Phase II trial of cetuximab in the treatment of persistent or recurrent squamous or non-squamous cell carcinoma of the cervix: a Gynecologic Oncology Group study.

Santin, Alessandro D

Phase II trial of cetuximab in the treatment of persistent or recurrent squamous or non-squamous cell carcinoma of the cervix: a Gynecologic Oncology Group study. [electronic resource] - Gynecologic oncology Sep 2011 - 495-500 p. digital

Publication Type: Clinical Trial, Phase II; Journal Article; Multicenter Study; Research Support, N.I.H., Extramural

1095-6859

10.1016/j.ygyno.2011.05.040 doi


Adult
Aged
Antibodies, Monoclonal--adverse effects
Antibodies, Monoclonal, Humanized
Antineoplastic Agents--adverse effects
Carcinoma, Squamous Cell--drug therapy
Cetuximab
Disease-Free Survival
Female
Humans
Middle Aged
Neoplasm Recurrence, Local--drug therapy
Survival Rate
Uterine Cervical Neoplasms--drug therapy